Navigation Links
Spectral's EAA(TM) to be used in Phase III study for a sepsis anti-endotoxin therapy
Date:4/9/2008

TORONTO, April 9 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc. (TSX: SDI) today announced that its Endotoxin Activity Assay (EAA(TM)), an FDA cleared diagnostic for risk of sepsis, will be used to measure endotoxin levels during the enrolment of patients in a Phase III sub study, part of a multinational clinical trial evaluating the safety and effectiveness of a treatment for severe sepsis.

"Spectral is pleased that a major international pharmaceutical company is using the EAA(TM) in a proportion of patients in its study," said Dr. Paul Walker, President and CEO of Spectral Diagnostics. "We are optimistic that the data from this sub study will promote subsequent use of the EAA(TM) to identify patients most likely to benefit from specific anti-endotoxin therapy."

Currently, in North America, there is no available drug to directly counter the effects of endotoxin. The Phase III sub study will explore the utility of partnering a reliable measurement of endotoxin, the EAA(TM), with a targeted anti-endotoxin treatment aimed at reducing mortality rates for patients with severe sepsis. Spectral's unique assay helps identify endotoxin levels in patients and enables appropriate and rapid application of therapeutics.

Spectral has a contractual agreement to supply EAA(TM) equipment, test kits and technical expertise for use in the study that is expected to run until mid 2010.

About Spectral Diagnostics

Spectral is a developer of innovative technologies for comprehensive disease management. Spectral's lead product is its EAA(TM) Endotoxin Activity Assay, the only FDA approved diagnostic for the measurement of endotoxin. Spectral technologies provide accurate and timely information to clinicians enabling the early initiation of appropriate and targeted therapy. Spectral is listed on TSX under the symbol SDI.

Forward-looking statement

Information in this news release that is not current or historical factual information
'/>"/>

SOURCE Spectral Diagnostics Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Spectral partner launches EAA(TM) Rapid Sepsis Diagnostic in Germany
2. Spectral announces data on the clinical utility of EAA(TM) to be presented at 12th Annual Critical Care for Endotoxemia Conference in Japan
3. Spectral announces new findings on the effectiveness of EAA(TM)/Toraymyxin(TM) at the 28th International Symposium on Intensive Care and Emergency Medicine
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
8. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
9. Phase III Trial Finds Pharmaxis Bronchitol Effective
10. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
11. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... (PRWEB) July 12, 2014 ... various reagents used in the life science ... the life science reagents market towards remarkable ... manufacturers and providers of life science reagents. ... Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The global ...
(Date:7/11/2014)... EPFL and the University of  Geneva ... John P. Donoghue . The American neuroscientist is ... . The new Wyss Center for Bio- ... Geneva , has named as its director one ... Donoghue , founder of Brown University,s Institute for Brain ...
(Date:7/10/2014)... July 10, 2014 Product and ... very low abundance and are often “lost in ... time-consuming. , Join presenters Dr. Rowel Tobias, Senior ... John Anders, Head of Quality at Nanotherapeutics, Inc., ... that can speed detection and quantitation while achieving ...
(Date:7/10/2014)... 10, 2014 Robert Harman, DVM, Founder and ... is proud to announce the relaunch of his highly informative ... new series called “ What are Stem Cells ?” ... and straightforward foundation in the basics of stem cell therapy ... the right type of treatment when considering regenerative medicine. , ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 2John P. Donoghue is Taking the Lead at the Wyss Center and is Appointed Professor at EPFL and University of Geneva 3Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... , COLUMBUS, Ohio, Nov. 30 The ... the nation,s first minority business early-stage capital summits. The ... "Transforming the Landscape of Business in America: A Minority Business ... national minority business leaders and local minority entrepreneurs. , ...
... Minn., Nov. 30 Acuo Technologies, developers of high-performance ... today announced contracting with Allina Hospitals and Clinics for ... of image storage across the Allina network of hospitals, ... on the Acuo Technologies DICOM Services Grid(TM) Software. ...
... , ... 2 (GPP2), a key guidance document for the publication of ... British Medical Journal (BMJ). "The publication of GPP2 in BMJ ... guidance for industry sponsored research and the publication of study ...
Cached Biology Technology:Ohio Capital Fund Announces Sponsorship of Minority Business Conference 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 2Acuo Technologies Announces Contract for Vendor Neutral Archive With Allina Hospitals and Clinics 3ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 2ISMPP Announces Publication of Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP2 Guidelines Published in the BMJ 3
(Date:7/11/2014)... Society shows that no-take zones in Belize can ... lobster, conch, and fish recover from overfishing, but ... The reporttitled "Review of the Benefits of No-Take ... no-take areas around the world. The report was ... in marine protected areas and fisheries management. The ...
(Date:7/11/2014)... Tenn., July 11, 2014--Researchers at the Department of ... R&D 100 awards, presented by R&D Magazine in ... , "These awards recognize the tremendous value of ... Moniz. "Research and development at the National Labs ... challenges and pursue the scientific and technological innovations ...
(Date:7/11/2014)... New South Wales, Australia when NASA,s Aqua satellite passed ... July 11 (12:35 p.m. local time/11:35 p.m. EDT on ... Wales (NSW), the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard ... spotted smoke (light brown) from various fires. Actively burning ... red. , The New South Wales, Australia Government website ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... , Today, Andrew Viterbi, Donald Bitzer and John Daugman ... Inventors Hall of Fame at the United States Patent ... and their accomplishments are in part a testimony to ... Viterbi, an electrical engineer and cofounder of wireless ...
... appearing in the Journal of Nutritional Biochemistry demonstrates that ... chronic high blood pressure (hypertension) by increasing the activity ... heart tissue. Grapes are a known natural source ... be responsible for the beneficial effects observed with grape ...
... that aimed to understand how the cancer drug everolimus ... trastuzumab has left researchers contemplating a puzzle. , The ... rates for some patients with early breast cancer when ... results suggest this benefit is achieved independently of the ...
Cached Biology News:New National Inventors Hall of Fame inductees received vital NSF support 2New National Inventors Hall of Fame inductees received vital NSF support 3New National Inventors Hall of Fame inductees received vital NSF support 4Study uncovers mechanism for how grapes reduce heart failure associated with hypertension 2Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer 2Study confirms everolimus can overcome trastuzumab resistance in HER-2 positive early breast cancer 3
... Anti-PRK2 MW 140kDa ... Immunogen Peptide spanning amino acids ... Purification immunoaffinity purified Quality ... RIPA lysates from HeLa cells. ...
...
Replacement Parts for Electrophoresis Apparatus...
Sprague-Dawley rats, 7-8 weeks old, mixed gender; tissue is collected fresh, frozen on dry ice within minutes of sacrifice and stored at -20C; individual tissue weight approx. 0.05 gram....
Biology Products: